Suggested remit - To appraise the clinical and cost effectiveness of midostaurin within its marketing authorisation for treating advanced systemic mastocytosis
 
Status In progress
Process STA 2018
ID number 1573

Provisional Schedule

Committee meeting 01 September 2020
Expected publication 11 November 2020

Project Team

Project lead Gemma Barnacle

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool

Consultees

Companies sponsors Novartis Pharmaceuticals (midostaurin)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Leukaemia CARE
  UK Mastocytosis Support Group
Professional groups Association of Cancer Physicians
  British Society for Haematology
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord-UK (imatinib) (confidentiality agreement not signed, not participating)
  Aurobindo Pharma - Milpharm (imatinib) (confidentiality agreement not signed, not participating)
  Bristol-Myers Squibb Pharmaceuticals (dasatinib) (confidentiality agreement not signed, not participating)
  Dr. Reddy's Laboratories (imatinib) (confidentiality agreement not signed, not participating)
  Generics UK (imatinib) (confidentiality agreement not signed, not participating)
  Intrapharm Laboratories (imatinib) (confidentiality agreement not signed, not participating)
  Janssen-Cilag (cladribine) (confidentiality agreement not signed, not participating)
  Lipomed (cladribine) (confidentiality agreement not signed, not participating)
  Merck Sharp & Dohme (cladribine, interferon alfa-2b) (confidentiality agreement not signed, not participating)
  Novartis Pharmaceuticals (imatinib, nilotinib) (confidentiality agreement not signed, not participating)
  Rivopharm UK (imatinib) (confidentiality agreement not signed, not participating)
  Roche (interferon alfa-2a) (confidentiality agreement not signed, not participating)
  Sandoz (imatinib) (confidentiality agreement not signed, not participating)
  Wockhardt UK (imatinib) (confidentiality agreement not signed, not participating)
Evidence review group Liverpool Reviews and Implementation Group (LRIG)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
18 December 2019 Invitation to participate
18 December 2019 In progress, ITP 18 December 2019
17 May 2019 - 17 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance